Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.99
CYTR's Cash-to-Debt is ranked lower than
72% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CYTR: 1.99 )
Ranked among companies with meaningful Cash-to-Debt only.
CYTR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: No Debt Max: No Debt
Current: 1.99
Equity-to-Asset 0.40
CYTR's Equity-to-Asset is ranked lower than
78% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTR: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
CYTR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.83 Max: 0.99
Current: 0.4
0.16
0.99
Piotroski F-Score: 4
Altman Z-Score: -11.85
Beneish M-Score: -3.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -24949.50
CYTR's Operating Margin % is ranked lower than
96% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CYTR: -24949.50 )
Ranked among companies with meaningful Operating Margin % only.
CYTR' s Operating Margin % Range Over the Past 10 Years
Min: -63278  Med: -12974.5 Max: -80.47
Current: -24949.5
-63278
-80.47
Net Margin % -24585.50
CYTR's Net Margin % is ranked lower than
95% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. CYTR: -24585.50 )
Ranked among companies with meaningful Net Margin % only.
CYTR' s Net Margin % Range Over the Past 10 Years
Min: -58587  Med: -10799.17 Max: 408
Current: -24585.5
-58587
408
ROE % -206.24
CYTR's ROE % is ranked lower than
90% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CYTR: -206.24 )
Ranked among companies with meaningful ROE % only.
CYTR' s ROE % Range Over the Past 10 Years
Min: -232.62  Med: -86.58 Max: 1.39
Current: -206.24
-232.62
1.39
ROA % -77.99
CYTR's ROA % is ranked lower than
79% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. CYTR: -77.99 )
Ranked among companies with meaningful ROA % only.
CYTR' s ROA % Range Over the Past 10 Years
Min: -116.2  Med: -46.69 Max: 1.13
Current: -77.99
-116.2
1.13
ROC (Joel Greenblatt) % -2371.30
CYTR's ROC (Joel Greenblatt) % is ranked lower than
73% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. CYTR: -2371.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYTR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12894.39  Med: -2849.72 Max: -723.27
Current: -2371.3
-12894.39
-723.27
3-Year Revenue Growth Rate -39.40
CYTR's 3-Year Revenue Growth Rate is ranked lower than
83% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CYTR: -39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYTR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.8  Med: -3.7 Max: 175.3
Current: -39.4
-81.8
175.3
3-Year EBITDA Growth Rate -11.10
CYTR's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. CYTR: -11.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYTR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.2  Med: -10.8 Max: 143.5
Current: -11.1
-67.2
143.5
3-Year EPS without NRI Growth Rate -24.10
CYTR's 3-Year EPS without NRI Growth Rate is ranked lower than
75% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CYTR: -24.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CYTR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -77.5  Med: -13 Max: 373.5
Current: -24.1
-77.5
373.5
GuruFocus has detected 2 Warning Signs with CytRx Corp $CYTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYTR's 30-Y Financials

Financials (Next Earnings Date: 2017-07-29 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ZFGN, NAS:OPHT, AMEX:PFNX, OTCPK:IMMVF, OTCPK:CYDY, AMEX:PLX, NAS:ORMP, NAS:AGTC, NAS:VCEL, NAS:PTI, NAS:MRTX, OTCPK:IPIX, OTCPK:HPPI, NAS:CDTX, NAS:CBMG, OTCPK:MCUJF, NAS:NVIV, OTCPK:EGRN, NAS:INFI, OTCPK:INNMF » details
Traded in other countries:CX5N.Germany,
Headquarter Location:USA
CytRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin.

CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
PB Ratio 5.40
CYTR's PB Ratio is ranked lower than
63% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CYTR: 5.40 )
Ranked among companies with meaningful PB Ratio only.
CYTR' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 3.55 Max: 67.04
Current: 5.4
1.39
67.04
PS Ratio 335.00
CYTR's PS Ratio is ranked lower than
94% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. CYTR: 335.00 )
Ranked among companies with meaningful PS Ratio only.
CYTR' s PS Ratio Range Over the Past 10 Years
Min: 3.5  Med: 210 Max: 2565
Current: 335
3.5
2565
Current Ratio 2.46
CYTR's Current Ratio is ranked lower than
68% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CYTR: 2.46 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.56 Max: 159
Current: 2.46
0.78
159
Quick Ratio 2.46
CYTR's Quick Ratio is ranked lower than
64% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CYTR: 2.46 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.56 Max: 159
Current: 2.46
0.78
159
Days Sales Outstanding 186.15
CYTR's Days Sales Outstanding is ranked lower than
88% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. CYTR: 186.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.94  Med: 326.31 Max: 16870.3
Current: 186.15
4.94
16870.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.10
CYTR's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CYTR: -37.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.9  Med: -16.9 Max: 5.8
Current: -37.1
-53.9
5.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.38
CYTR's Price-to-Net-Cash is ranked lower than
52% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. CYTR: 8.38 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYTR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.55  Med: 6.7 Max: 458
Current: 8.38
0.55
458
Price-to-Net-Current-Asset-Value 6.09
CYTR's Price-to-Net-Current-Asset-Value is ranked higher than
56% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CYTR: 6.09 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYTR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.43  Med: 4.14 Max: 108.89
Current: 6.09
0.43
108.89
Price-to-Tangible-Book 5.58
CYTR's Price-to-Tangible-Book is ranked lower than
54% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. CYTR: 5.58 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYTR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.34  Med: 3.56 Max: 153.05
Current: 5.58
0.34
153.05
Price-to-Median-PS-Value 1.60
CYTR's Price-to-Median-PS-Value is ranked lower than
78% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CYTR: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.19 Max: 9.95
Current: 1.6
0.01
9.95
Earnings Yield (Greenblatt) % -57.80
CYTR's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. CYTR: -57.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13932  Med: -38.8 Max: 3114.3
Current: -57.8
-13932
3114.3

More Statistics

Revenue (TTM) (Mil) $0.20
EPS (TTM) $ -0.56
Beta1.65
Short Percentage of Float12.82%
52-Week Range $0.36 - 2.67
Shares Outstanding (Mil)152.05

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 11 28
EPS ($) -0.41 -0.21
EPS without NRI ($) -0.41 -0.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
CytRx Announces Reshaping of Clinical and Regulatory Executive Team Jun 13 2017 
CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas Jun 08 2017 
CytRx Reports First Quarter 2017 Financial Results May 10 2017 
CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock Apr 28 2017 
CytRx Corporation Announces Proposed Public Offering of Common Stock Apr 27 2017 
CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 Apr 21 2017 
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sar Apr 19 2017 
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 

More From Other Websites
CytRx Announces Reshaping of Clinical and Regulatory Executive Team Jun 13 2017
Today's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation Jun 09 2017
CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas Jun 08 2017
Goodbye CytRx, Your Game Is Over Jun 05 2017
Penny Stocks to Watch for June 2017 May 31 2017
Today's Research Reports on Stocks to Watch: Endocyte and CytRx May 31 2017
The Most Notable Abstracts Released Ahead Of ASCO 2017 May 19 2017
Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx May 19 2017
CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at... May 17 2017
CytRx reports 1Q loss May 10 2017
CytRx Reports First Quarter 2017 Financial Results May 10 2017
CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock Apr 28 2017
CytRx Corporation Announces Proposed Public Offering of Common Stock Apr 27 2017
Penny Stocks to Watch for May 2017 Apr 27 2017
CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017... Apr 21 2017
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up Apr 20 2017
ETFs with exposure to CytRx Corp. : April 20, 2017 Apr 20 2017
Blog Coverage CytRx Announces FDA's Approval for New Drug Application Apr 20 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue... Apr 19 2017
For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1 Apr 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}